TOP2B and cardiomyopathy: The current literature supports the hypothesis that the pathophysiology of anthracycline-induced cardiomyopathy is largely dependent on the targeting of Topoisomerase II beta (TOP2B) in cardiomyocytes, an increase in oxidative stress, and the disruption of mitochondrial homeostasis [18, 19].